Dual-target synergistic antithrombotic mechanism of a dabigatran etexilate analogue (HY023016).

Wan, Sheng; Cui, Shuang; Jiang, Minrui; Wu, Qian; Ji, Yingying; Xu, Yungen; Gong, Guoqing

Wan, Sheng; Cui, Shuang; Jiang, Minrui; Wu, Qian; Ji, Yingying; Xu, Yungen; Gong, Guoqing.

Afiliação

Wan S; Department of Pharmacology, China Pharmaceutical University, Nanjing, China.
Cui S; Department of Pharmacology, China Pharmaceutical University, Nanjing, China.
Jiang M; Department of Pharmacology, China Pharmaceutical University, Nanjing, China.
Wu Q; Department of Pharmacology, China Pharmaceutical University, Nanjing, China.
Ji Y; Department of Pharmacology, China Pharmaceutical University, Nanjing, China.
Xu Y; Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing, China.
Gong G; Department of Pharmacology, China Pharmaceutical University, Nanjing, China.

Clin Exp Pharmacol Physiol ; 49(5): 567-576, 2022 05.

Article em En | MEDLINE | ID: mdl-35147244

Assuntos

Dabigatrana; Fibrinolíticos; Animais; Anticoagulantes; Dabigatrana/farmacologia; Dabigatrana/uso terapêutico; Fibrinolíticos/farmacologia; Fibrinolíticos/uso terapêutico; Ratos; Trombina/metabolismo

Palavras-chave

GPIbα; dual-target; platelet membrane glycoproteins; thrombin; thrombin exosite II

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fibrinolíticos / Dabigatrana Tipo de estudo: Prognostic_studies Limite: Animals Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google